- Home
- » Tags
- » Semaglutide
Top View
- An Overview of GLP-1 Agonists and Recent Cardiovascular Outcomes Trials Kelsey H Sheahan ,1 Elizabeth a Wahlberg,2 Matthew P Gilbert1
- Once-Weekly Semaglutide for Patients with Type 2 Diabetes
- Structure and Dynamics of Semaglutide and Taspoglutide Bound GLP-1R-Gs Complexes Xin Zhang1, Matthew J
- Clinical Review Hyon Kwon, Pharmd, MPH Snda 208751/S-010 and S-011 Fiasp (Insulin Aspart)
- Injectables That Lower Glucose
- Therapeutic Class Overview Therapeuticincretin Mimeticsclass Overview & Amylinomimetics
- Semaglutide Subcutaneous Once-Weekly
- Hmmc Semaglutide (Ozempic ) for Adults with Type 2 Diabetes
- Addressing Hesitancy in Treatment Intensification
- Addressing Hesitancy in Treatment Intensification Beyond Basal Insulin
- Safety of Semaglutide
- Blue Cross and Blue Shield October 2019 Multi-Tier Basic Drug List I How to Use This List Generic Drugs Are Shown in Lower-Case Boldface Type
- What Hospitalists Need to Know About Diabetes…
- The Human GLP-1 Analogs Liraglutide and Semaglutide: Absence of Histopathological Effects on the Pancreas in Nonhuman Primates
- Efficacy of Semaglutide in a Subcutaneous and an Oral
- Type 2 Meds Management Update. Objectives 1
- Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide
- Zealand Pharma in 2019
- Semaglutide, a Glucagon‑Like Peptide 1 Receptor Agonist (Review)
- Oral Semaglutide Versus Empagliflozin in Patients with Type 2 Diabetes Uncontrolled on Metformin: the PIONEER 2 Trial
- Advances in Therapeutic Peptides Targeting G Protein-Coupled Receptors
- Semaglutide (Ozempic®)
- Superior Weight Loss with Once-Weekly Semaglutide Versus Other Glucagon-Like Peptide-1 Receptor Agonists Is Independent of Gastr
- Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo
- Discovery Awaits You at the 81ST Scientific Sessions
- 5.01.569 Pharmacotherapy of Type I and Type II Diabetes Mellitus
- Effect of Subcutaneous Semaglutide Vs Placebo As an Adjunct To
- Intensive Insulin Management and Basal/Bolus Therapy
- GLP-1 Agonists
- OZEMPIC (Semaglutide) Injection, for Subcutaneous Use Initial U.S
- Systematic Review and Meta-Analysis for Prevention of Cardiovascular
- Interim Report for Q1 2020
- Ozempic, INN-Semaglutide
- GLP-1 Receptor Agonists and Diabetic Kidney Disease: a Call of Attention to Nephrologists
- Initial Injectable Therapy in Type 2 Diabetes: Key Considerations When Choosing Between Glucagon-Like Peptide 1 Receptor Agonists and Insulin
- DIWC Newsletter April 2021
- Semaglutide Injection)
- Drugs for Diabetes
- Oral Semaglutide Versus Empagliflozin in Patients with Type 2 Diabetes Uncontrolled on Metformin: the PIONEER 2 Trial
- Latest Advances in the Management of Diabetes
- Oral Semaglutide for the MACE Indication Is Expected to Be Completed in the Sally Hughes and Joshua J
- Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER
- Transcripts Are Based, Companies May Make Projections Or Other Forward-Looking Statements Regarding a Variety of Items
- Ozempic (Semaglutide) Rybelsus (Semaglutide) Tablets Soliqua (Insulin Glargine and Lixisenatide) Xultophy (Insulin Degludec and Liraglutide) Effective 01/01/2021
- Evidencefinder Last Updated May 7, 2020
- Novo Nordisk Patient Assistance Program (PAP) Available Products
- Zealand Pharma Interim Report for Q3 2020
- 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2021